SCHEMBL5885340

SCHEMBL5885340

O=C(O)c1cc2ccsc2n1Cl

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 1/20 0.46
RCOR1 Q9UKL0 1/20 0.46
DAO P14920 2/20 0.39
TSHR P16473 4/20 0.38
L3MBTL1 Q9Y468 3/20 0.36
LMNA P02545 2/20 0.36
MAPT P10636 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
TP53 P04637 1/20 0.36
POLB P06746 1/20 0.36
MCL1 Q07820 1/20 0.35
CCR2 P41597 1/20 0.35
ALDH1A1 P00352 3/20 0.34
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
USP2 O75604 1/20 0.34
ABCB11 O95342 1/20 0.34
ESR1 P03372 1/20 0.34
GPR35 Q9HC97 2/20 0.33
CTNNB1 P35222 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5730537 0.86 KDM1A (0.42) KDM1ARCOR1DAOTSHRL3MBTL1
SCHEMBL17554479 0.79 KDM1A (0.64) KDM1ARCOR1DAOTSHRL3MBTL1
SCHEMBL2331226 0.72 KDM1A (0.47) KDM1ARCOR1TSHRL3MBTL1LMNA
SCHEMBL28833751 0.71 L3MBTL1 (0.43) KDM1ARCOR1TSHRL3MBTL1LMNA
SCHEMBL28535946 0.70 KDM1A (0.39) KDM1ARCOR1DAOTSHRL3MBTL1
SCHEMBL28538325 0.70 NOTUM (0.41) KDM1ARCOR1TSHRL3MBTL1LMNA
SCHEMBL19610319 0.70 KDM1A (0.58) KDM1ARCOR1TSHRL3MBTL1LMNA
SCHEMBL28551725 0.69 TSHR (0.47) KDM1ARCOR1TSHRL3MBTL1LMNA
SCHEMBL28783733 0.69 KDM1A (0.41) KDM1ARCOR1TSHRL3MBTL1LMNA
SCHEMBL14948821 0.69 KDM1A (0.38) KDM1ARCOR1TSHRLMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6992101-B2 N-(indole-2-carbonyl) and H-thieno[2,3-b]pyrrole-5-carboxamide anti-diabetic agents PFIZER, INC. (US) 2006-01-31 US disclosed
EP-1562899-A2 N-(INDOLE-2-CARBONYL)AMIDES AS ANTI-DIABETIC AGENTS Pfizer Products Inc. (US) 2005-08-17 EP disclosed
US-20040157907-A1 Anti-diabetic agents PFIZER INC 2004-08-12 US disclosed
WO-2004041780-A2 N-(INDOLE-2-CARBONYL) AMIDES AS ANTI-DIABETIC AGENTS PFIZER PRODUCTS INC. (US) 2004-05-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040157907-A1 Anti-diabetic agents GPR119, INSR, IRS1 KDM1A 3600/4885RCOR1 818/4885DAO 2573/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.